Adolescents prefer long-acting injectables to daily oral treatment, study finds
NAM Aidsmap News | HIV & AIDS Information
by Mercy Shibemba
15h ago
How young people feel about long-acting injectable treatment remains largely unexplored. The More Options for Children and Adolescents (MOCHA) study provides some insight into the experiences of young people aged 12-18 who have switched to long-acting cabotegravir / rilpivirine based treatment. It is the first to examine use of long-acting injectable antiretrovirals in virally suppressed adolescents ..read more
Visit website
Almost two-thirds of new HIV cases occur outside southern and eastern Africa
NAM Aidsmap News | HIV & AIDS Information
by Keith Alcorn
15h ago
Almost two-thirds of new cases of HIV now occur outside countries with high HIV prevalence in southern and eastern Africa, according to an analysis of UNAIDS country-level data presented earlier this month at the Conference on Retroviruses and Opportunistic Infections (CROI 2024) in Denver ..read more
Visit website
Top 5 stories on HIV in the US from CROI 2024
NAM Aidsmap News | HIV & AIDS Information
by Greta Hughson
15h ago
The Conference on Retroviruses and Opportunistic Infections (CROI 2024), took place earlier this month with research from around the world. Here is a roundup of research focused on the US ..read more
Visit website
People who inject drugs in the US are more aware of PrEP, but aren’t taking it
NAM Aidsmap News | HIV & AIDS Information
by Krishen Samuel
3d ago
While 1 in 3 people who inject drugs were aware of PrEP in 2022, only 1 in 100 actually took it. Despite changes in PrEP awareness between 2018 and 2022, increases in uptake for this vulnerable group were small, according to data presented to the Conference on Retroviruses and Opportunistic Infections (CROI 2024) earlier this month in Denver by Dr Patrick Eustaquio ..read more
Visit website
Top 5 stories on injectable HIV treatment and PrEP from CROI 2024
NAM Aidsmap News | HIV & AIDS Information
by Greta Hughson
3d ago
Long-acting injectable HIV treatment and PrEP (medication to prevent HIV) continue to be areas of interest and progress in the HIV field. Some of the latest research on injectable treatment and PrEP was presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2024) earlier this month and we have put together some highlights below ..read more
Visit website
Over 30 years, big fall in HIV among people who inject drugs in Baltimore, but hepatitis C remains high
NAM Aidsmap News | HIV & AIDS Information
by Krishen Samuel
5d ago
Despite less injecting drug use, increased use of harm reduction services, and significant progress in reducing HIV infections, there has been a resurgence of hepatitis C among people who inject drugs in recent years in Baltimore, especially among people under the age of 40. This research, tracking changes over the past three decades, was presented by Eshan Patel to the recent Conference on Retroviruses and Opportunistic Infections (CROI 2024) in Denver ..read more
Visit website
Top 5 stories on HIV and women from CROI 2024
NAM Aidsmap News | HIV & AIDS Information
by Greta Hughson
5d ago
The Conference on Retroviruses and Opportunistic Infections (CROI 2024) was held in Denver, US, in March. Here is a roundup of some of the HIV treatment and prevention research focused on women that was presented at the conference ..read more
Visit website
Top 5 HIV PrEP stories from CROI 2024
NAM Aidsmap News | HIV & AIDS Information
by Greta Hughson
1w ago
One of the most important HIV conferences of the year, the Conference on Retroviruses and Opportunistic Infections (CROI 2024), took place earlier this month. Here are some highlights from research on PrEP (regular medication to prevent HIV) presented at CROI ..read more
Visit website
Long-acting injectables can be a good option for people with adherence challenges
NAM Aidsmap News | HIV & AIDS Information
by Liz Highleyman
1w ago
Antiretroviral therapy (ART) using cabotegravir and rilpivirine injections monthly or every other month can be an effective HIV treatment option for people who have difficulty maintaining viral suppression on daily pills due to suboptimal adherence, according to studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2024 ..read more
Visit website
Top 5 stories on co-morbidities affecting people with HIV from CROI 2024
NAM Aidsmap News | HIV & AIDS Information
by Greta Hughson
1w ago
Co-morbidities – other health issues affecting people with HIV – continue to be an important focus of research in the HIV field. Here are some of the top stories on co-morbidities research presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2024 ..read more
Visit website

Follow NAM Aidsmap News | HIV & AIDS Information on FeedSpot

Continue with Google
Continue with Apple
OR